Generation of CD20-specific TCRs for TCR gene therapy of CD20(low) B-cell malignancies insusceptible to CD20-targeting antibodies

Immunotherapy of B-cell leukemia and lymphoma with CD20-targeting monoclonal antibodies (mAbs) has demonstrated clinical efficacy. However, the emergence of unresponsive disease due to low or absent cell surface CD20 urges the need to develop additional strategies. In contrast to mAbs, T-cells via t...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Jahn, Lorenz, van der Steen, Dirk M., Hagedoorn, Renate S., Hombrink, Pleun, Kester, Michel G.D., Schoonakker, Marjolein P., de Ridder, Daniëlle, van Veelen, Peter A., Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2016
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363567/
https://ncbi.nlm.nih.gov/pubmed/27776339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12778
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items